Abstract:Rapamycin is a triene macrolide antibiotic produced by Streptomyces hygroscopicus. Besides its wide application as an effective immunosuppressive agent, other important bioactivities have made rapamycin a potential drug lead for novel pharmaceutical development. However, the low titer of rapamycin in the original producer strain limits further industrialization efforts and restricts its use for other applications. Predicated on knowledge of the metabolic pathways related to rapamycin biosynthesis in S. hygroscopicus, we have rationally designed approaches to generate a rapamycin high producer strain of S. hygroscopicus HD-04-S. These have included alleviation of glucose repression, improved tolerance towards lysine and shikimic acid, and auxotrophy of tryptophan and phenylalanine through the application of stepwise UV mutagenesis. The resultant strain produced rapamycin at 450 mg/L in the shake flask scale. These fermentations were further scaled up in 120 and 20,000 L fermentors, respectively, at the pilot plant. Selected fermentation factors including agitation speed, pH, and on-line supplementation were systematically evaluated. A fed-batch strategy was established to maximize rapamycin production. With these efforts, an optimized fermentation process in the larger scale fermentor was developed. The final titer of rapamycin was 812 mg/L in the 120 L fermentor and 783 mg/L in the 20,000 L fermentor. This work highlights a high rapamycin producing strain derived by mutagenesis and subsequent screening, fermentation optimization of which has now made it feasible to produce rapamycin on an industrial scale by fermentation. The strategies developed here should also be applicable to titer improvement of other important microbial natural products on an industrial scale. Biotechnol. Bioeng. 2010; 107: 506-515. (C) 2010 Wiley Periodicals, Inc.

7-O-ethyl-rapamycin produced by rapamycin producing strain mutant FC904-107

Isolation and identification of rapamycin dialdehyde

Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization.

14-deoxorapamycin, the microbial conversion product of rapamycin by Micromonospora chersina FIM03-712

43-O-(β-d-glucoside)-rapamycin, a Microbial Conversion Product by Bacillus Subtilis CGMCC7764

Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis

41-Azido-41-deoxyrapamycin

Insights into the Metabolic Mechanism of Rapamycin Overproduction in the Shikimate-Resistant Streptomyces Hygroscopicus Strain Uv-Ii Using Comparative Metabolomics

Separation and identification of Rap-D1,the isomer of sirolimus

Comparative analysis of rapamycin biosynthesis clusters between Actinoplanes sp. N902-109 and Streptomyces hygroscopicus ATCC29253

Isolation, Structure Determination and Biological Activity of 15-Deoxo-7,32-o-didesmethylrapamycin from the Soil Actinomycete Ll-D45042

Novel sulfur-containing rapamycin analogs prepared by precursor-directed biosynthesis.

Coupled cell morphology investigation and metabolomics analysis improves rapamycin production in Streptomyces hygroscopicus

Comparative Metabolic Profiling-Based Improvement of Rapamycin Production by Streptomyces Hygroscopicus

Structure of prolylrapamycin: confirmation through a revised and detailed NMR assignment study

Comparative Metabolic Profiling Reveals the Key Role of Amino Acids Metabolism in the Rapamycin Overproduction by Streptomyces Hygroscopicus

Bioactive Metabolites from Marine-Derived Streptomyces Sp A68 and Its Rifampicin Resistant Mutant Strain R-M1

Rifamycin Biosynthetic Congeners: Isolation and Total Synthesis of Rifsaliniketal and Total Synthesis of Salinisporamycin and Saliniketals A and B

Enhancement of Rapamycin Production by Metabolic Engineering in Streptomyces Hygroscopicus Based on Genome-Scale Metabolic Model

In Vivo Investigation of the Role of SfmO2 in Saframycin A Biosynthesis by Structural Characterization of the Analogue Saframycin O

Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used As Potential Mtor‐targeted Anticancer Agents